



Second Quarter 2007 Investor Deck

August 8, 2007

Forward Looking Statements

This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements concern expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. Specifically, this presentation contains forward-looking statements regarding our estimates of revenues, earnings and expected gains in market share in future periods. These forward-looking statements reflect our current views about future events and are subject to risks that could cause actual results to differ significantly. The risks that could prevent us from achieving our goals, and cause the assumptions underlying forward-looking statements and the actual results to differ materially from those expressed in or implied by those forward-looking statements include, but are not limited to, the risks contained in our Annual Report on Form 10-K for the year ended December 31, 2006 and our Quarterly Report on Form 10-Q for the three months ended June 30, 2007, each of which can be accessed electronically in the Investor Relations portion of our web site at www.inventivhealth.com.

This presentation includes non-GAAP financial measures within the meaning of Regulation G of the Securities and Exchange Commission. The "adjusted" (non-GAAP) financial measures included in this presentation exclude the following:

- *compensation expense related to vested stock options and restricted stock;*
- *interest income (expense) related to our interest rate hedge of a term loan facility;*
- *a receivables reserve recorded during the second quarter of 2007;*
- *federal tax benefits related to state and local tax exposure; and*
- *costs attributable to an acquisition-related incentive plan.*

We believe that these non-GAAP financial measures are a more accurate basis for evaluating ongoing performance and planning and forecasting of future periods, and we use these non-GAAP financial measures internally for the foregoing purposes. We have included in the appendices to this presentation the most directly comparable GAAP financial measures and a reconciliation between the non-GAAP and GAAP financial measures.

All segment information contained in this presentation excludes corporate overhead, minority interest & equity investments.

The sum of the net earnings per share do not add up to the half year amount for 2007 due to rounding and because the quarterly calculations are based on varying numbers of shares outstanding.

First Half and Second Quarter 2007 vs. 2006

\$'s in Millions (except per share)

	H1:07	H1:06	% Δ	Q2:07	Q2:06	% Δ
Gross Revenues	\$454.4	\$356.7	27%	\$232.4	\$183.0	27%
Net Revenues	\$369.8	\$297.7	24%	\$193.5	\$154.7	25%
Adjusted EBITDA	\$59.3	\$52.6	13%	\$32.5	\$27.3	19%
Adjusted Operating Income	\$46.9	\$42.4	11%	\$25.8	\$21.9	18%
Adjusted Net Income	\$24.7	\$21.2	17%	\$13.7	\$11.2	22%
Adjusted Diluted EPS	\$0.78	\$0.71	9%	\$0.43	\$0.37	16%

NOTE: Investors are referred to the reconciliations to GAAP provided at the end of this presentation.


NOTE: The adjusted Net Income and adjusted EPS figures present adjusted results from continuing operations.

NOTE: The adjusted EBITDA and adjusted Operating Income figures exclude minority interest and equity investment


H1:07 Segment Performance

\$'s in Millions

Gross Revenue



Adjusted Operating Income



 Clinical  Communications  Commercial


NOTE: Investors are referred to the reconciliations to GAAP provided at the end of this presentation.




Q2:07 Segment Performance

\$'s in Millions

Gross Revenue



Adjusted Operating Income



 Clinical  Communications  Commercial

NOTE: Investors are referred to the reconciliations to GAAP provided at the end of this presentation.

Clinical: First Half and Second Quarter Review

\$'s in Millions

	H1:07	H1:06	% Δ	Q2:07	Q2:06	% Δ
Gross Revenues	\$88.4	\$70.9	25%	\$47.0	\$38.4	22%
Adjusted Operating Income	\$5.4	\$5.5	-2%	\$3.2	\$3.9	-18%
Adjusted Operating Income %	6.1%	7.8%		6.8%	10.2%	

- Awarded a major “Functional Outsourcing” contract by a Top 20 Pharma company.
- The aforementioned contract required a material infrastructure investment by inVentiv Clinical in H1:07.
- Revenues in the clinical division were higher in 2007 predominantly due to increased placement of temporary personnel and growth in functional outsourcing.

NOTE: Investors are referred to the reconciliations to GAAP provided at the end of this presentation.

Communications: First Half and Second Quarter Review

\$'s in Millions

	H1:07	H1:06	% Δ	Q2:07	Q2:06	% Δ
Gross Revenues	\$165.9	\$117.0	42%	\$85.7	\$64.5	33%
Adjusted Operating Income	\$25.1	\$17.6	43%	\$13.2	\$8.8	50%
Adjusted Operating Income %	15.1%	15.0%		15.4%	13.6%	

•Growth drivers for the business included new client wins and meaningful expansion of existing accounts in the agency and patient compliance businesses as well as the performance of acquired companies.

•Ignite, Chamberlain & Addison Whitney are newly acquired businesses and contributed to H1:07 results.

NOTE: Investors are referred to the reconciliations to GAAP provided at the end of this presentation.

Commercial: First Half and Second Quarter Review

\$'s in Millions


	H1:07	H1:06	% Δ	Q2:07	Q2:06	% Δ
Gross Revenues	\$200.1	\$168.8	19%	\$99.8	\$80.0	25%
Adjusted Operating Income	\$23.0	\$24.1	-5%	\$12.8	\$11.6	10%
Adjusted Operating Income %	11.5%	14.3%		12.8%	14.5%	

- **Contract teams business maintaining 40%+ market share.**
- **Comparing H1:07 to H1:06, the Commercial business replaced two large sales team client contracts and benefited from several new wins.**
- **H1:07 margins were impacted unfavorably by business mix and the ramp-up of certain new programs, including a significant ‘on-boarding’ contract for a Top 10 Pharma client.**

NOTE: Investors are referred to the reconciliations to GAAP provided at the end of this presentation.

New Business Pipeline – Annualized Net Fees

\$'s in Millions



NOTE: inVentiv calculates its pipeline based on its approximate annualized net revenue estimate for all identified new business opportunities on a rolling, forward 12-mth basis. The Q2:07 figure excludes AWAC & CCA (closed after 6/30/07).

NOTE: inVentiv has historically won ~50% of the opportunities for which inVentiv submits a proposal and the Client elects to outsource (weighted by net revenue).

ProForma Organic Net Revenue Growth

	2003 to 2006 3-Yr CAGR	H1:07 vs. H1:06 % Δ	Comments
Clinical	22.6%	23.6%	<ul style="list-style-type: none"> •Growth rate is roughly 1.5x the clinical outsourcing market's growth rate.¹ •Continuing to gain share based on our differentiated model and strong execution.
Communications	26.1%	14.0%	<ul style="list-style-type: none"> •Historical growth rate significantly in excess of 8-10% growth rate that inVentiv estimates for the market. • inVentiv expects to continue outpacing the market rate of growth, due in part to the rapid growth of the Adheris patient compliance business.
Commercial	11.7%	10.8%	<ul style="list-style-type: none"> •Continues to benefit from industry trend towards cost-efficient solutions. •“On-boarding” could lead to a more recurring business model over the medium-to-long-term.
Total	18.2%	14.6%	

NOTE: Pre-acquisition proforma numbers may be unaudited and may be reflected wholly or partially on a cash basis. Gross revenues were used as a proxy for net revenues if the acquired companies did not segregate customer reimbursements.

NOTE: Each company acquired as of 6/30/07 is assumed as part of inVentiv proforma net revenues from 1/1/03 as if they were wholly-owned by the company. AWAC & CCA have been excluded from this analysis (acquired after 6/30/07).


SOURCE: ¹Increased Biotechnology Funding Boosts U.S. Drug Discovery, Frost & Sullivan, 11/24/06.

Net Revenue Growth


(\$'s in Millions)

As exhibited below, inVentiv has delivered strong net revenue growth through a combination of strategic acquisitions and related strong organic growth.

As Reported



ProForma Organic



 Clinical  Communications  Commercial

NOTE: Pre-acquisition proforma numbers may be unaudited and may be reflected wholly or partially on a cash basis. Gross revenues were used as a proxy for net revenues if the acquired companies did not segregate customer reimbursements.

NOTE: Proforma Organic Net Revenue - Each company acquired as of 6/30/07 is assumed as part of inVentiv proforma organic net revenues as if they were wholly-owned by inVentiv as of 1/1/03. AWAC & CCA have been excluded from this analysis (acquired after 6/30/07).

2007 Guidance

	2006	2007E	2007E vs. 2006 % Δ
Revenue	\$766.2M	\$950 to \$970M	24 – 27%
Adjusted EPS	\$1.52	\$1.79 to \$1.89	18 – 24%
Adjusted EPS (w/ Stock Comp.)	\$1.37	\$1.59 to \$1.69	16 – 23%

NOTE: Adjusted EPS figures for all periods exclude equity compensation expense (except where noted), acquisition-related incentive plan, interest income or expense related to the Company's interest rate hedge on its term loan facility, certain receivables reserves and any non-recurring tax adjustments. Investors are referred to the reconciliations to GAAP provided at the end of this presentation.



Appendix

Pharma & Life Sciences Client Statistics

- **inVentiv supports more than 250 unique pharma and life sciences clients.**
- **On average, an inVentiv Client utilizes 2.7 inVentiv service offerings.**
- **inVentiv continues to work with all 20 of the “Top 20” global pharmaceutical manufacturers.**
 - One “Top 20” customer utilizes 25 inVentiv services.
 - One “Top 20” customer utilizes 16 inVentiv services.
 - Four “Top 20” customers utilize 14 inVentiv services.
- ***Significant Cross-Selling Opportunity* – Of more than 250 unique pharma and life sciences clients, only 44% utilize more than 1 inVentiv service.**
- **Since Q1:06, inVentiv has made 165 joint-pitches for master service contracts that would utilize offerings from inVentiv companies within 2 or more segments.**

NOTE: All client utilization information has been consolidated by client's parent entity. Pharma & Life Science Client defined as a developer, manufacturer or marketer of ethical pharmaceutical, OTC, diagnostic or device products. These figures exclude AWAC & CCA (acquired after 6/30/07).



Metrics & Other Information

Metric	6/30/07	3/31/07	12/31/06
Adjusted Free Cash Flow (qtr) ¹	\$19.5M	\$12.9M	\$11.8M
Cash Balance (qtr)	\$41.6M	\$46.4M	\$79.9M
Working Capital (qtr)²	\$87.0M	\$92.9M	\$86.7M
Leverage Ratio (Proforma ttm) ³	1.90	1.91	1.78
Days Sales Outstanding (qtr)	71	77	73
Total Enterprise Value / Adjusted EBITDA (ttm) ⁴	11.5	12.2	10.7
Approximate Worldwide Employee Count (qtr) ⁵	5,700	5,200	5,200

NOTE: For metrics definitions and notes please see following page. Investors are referred to the reconciliations to GAAP provided at the end of this presentation.

Metrics Definitions & Notes

¹ Adjusted Free Cash Flow = GAAP Net Income + Depreciation + Amortization + Equity Compensation Expense + Receivables Reserves +/- Derivative Interest, Net of Tax – PP&E – Capital Leases

² Working Capital = Current Assets – Current Liabilities

³ Leverage Ratio (TTM) - calculated as if all companies acquired by 6/30/07 were part of inVentiv as of 7/1/06 = Debt / Adjusted EBITDA *

* Adjusted EBITDA as defined within inVentiv's credit agreement with UBS.

⁴ Total Enterprise Value / Adjusted EBITDA (TTM) ** = (Market Cap.* + Debt + Minority Interest – Cash & Cash Equivalents) / Adjusted EBITDA**

**EBITDA figures used in TEV/Adjusted EBITDA metric excludes minority interest, equity investments, equity compensation expense, acquisition-related incentive plan, interest income or expense related to the Company's interest rate hedge on its term loan facility, certain receivables reserves and any non-recurring tax adjustments.

***Market Cap. defined as market price per share at the end of the period multiplied by the shares outstanding at the end of the period.

⁵ Excludes ~330 employees from Chandler Chicco Agency & AWAC (acquisitions closed after 6/30/07).

Recent Developments

Acquisitions:

- Chandler Chicco Agency (July 2007)
 - Business: Healthcare public relations & advertising firm
 - Locations: California, London, New York, Paris, Washington D.C.
 - Consideration: \$65M up-front + potential earn-out
- AWAC (July 2007)
 - Business: Medical cost containment, disease management & wellness
 - Location: Georgia
 - Consideration: \$75M up-front + potential earn-out
- Addison Whitney (June 2007)
 - Business: Global brand identity & consulting firm
 - Location: North Carolina
 - Consideration: \$18M up-front + potential earn-out
- Strategyx (June 2007)
 - Business: Healthcare consulting & market research firm
 - Location: New Jersey
 - Consideration: \$8.5M up-front + potential earn-out

Recent Developments (Continued)

New Strategic Alliance:

- Announced agreement with ClinPhone, a leading clinical technology organization (June 2007)
 - New inVentiv capability: electronic data capture (EDC) for clinical trials

New Service Offering:

- inVentiv Resource Solutions launched (July 2007)
 - New inVentiv capabilities: recruiting & professional development webportal, temporary staffing business, human resources consulting
 - Partnering with Post University for professional development

New Reporting Segment:

- inVentiv Patient Outcomes (effective Q3:07)
 - Combines inVentiv's patient-focused offerings

Acquisition History

<u>Company</u>	<u>Date</u>	<u>Segment</u>	<u>Up-Front Consideration</u>
AWAC	July '07	TBD	\$75M
Chandler Chicco Agency	July '07	Communications	\$65M
Addison Whitney	June '07	Communications	\$18M
Strategyx	June '07	Commercial	\$8.5M
Chamberlain Healthcare	Mar '07	Communications	\$13M
Ignite Health	Mar '07	Communications	\$20M
DialogCoach	Nov '06	Commercial	\$5M
MedConference	Nov '06	Commercial	\$7M
Jeffrey Simbrow Associates	Apr '06	Communications	\$10M (Canadian)
Synergos	Apr '06	Clinical	\$5.75M
Adheris	Feb '06	Communications	\$60M
inChord Communications	Oct '05	Communications	\$185M
PRS	Aug '05	Commercial	\$13M
HHI	Nov '04	Clinical	\$5.8M
Smith Hanley	Oct '04	Clinical	\$50M
Franklin Group	Jun '04	Commercial	\$10M

Non-GAAP Reconciliations

Reconciliation of Adjusted Operating Income and Adjusted EBITDA

(in millions)	Second Quarter		First Half	
	2007	2006	2007	2006
Operating income, as reported	\$ 15.1	\$ 20.2	\$ 33.7	\$ 39.1
Add: Equity compensation expense	2.5	1.7	5.0	3.3
Add: Receivable reserve	8.2	--	8.2	--
Adjusted operating income	25.8	21.9	46.9	42.4
Add: Depreciation	4.6	3.8	8.5	7.6
Add: Amortization	2.1	1.6	3.9	2.6
Adjusted EBITDA *	\$ 32.5	\$ 27.3	\$ 59.3	\$ 52.6

* before minority interest in income of subsidiary and income (loss) from equity investments

Reconciliation of Adjusted Net Income from Continuing Operations and Adjusted Diluted EPS from Continuing Operations

(in millions)	Second Quarter		First Half	
	2007	2006	2007	2006
Net income from Continuing Operations	\$ 7.2	\$ 19.9	\$ 17.6	\$ 30.0
Add: Equity compensation expense, net of taxes	1.5	1.1	2.9	2.0
Add: Receivable reserve, net of taxes	4.8	--	4.8	--
Add (Subtract): Derivative interest, net of taxes	0.2	(0.7)	0.4	(1.7)
Deduct: Tax benefit	--	(9.1)	(1.0)	(9.1)
Adjusted Net income from Continuing Operations	\$13.7	\$11.2	\$24.7	\$21.2
Diluted Shares Outstanding	32.0	30.2	31.6	29.7
Adjusted Diluted EPS from Continuing Operations	\$0.43	\$0.37	\$0.78*	\$0.71

* The sum of the adjusted net earnings per share do not add up to the first half amount due to rounding and because the quarterly calculations are based on varying number of shares outstanding.

Reconciliation of Segment Operating Income

(in millions)	inVentiv Clinical				inVentiv Commercial				inVentiv Communications			
	Q207	Q206	H107	H106	Q207	Q206	H107	H106	Q207	Q206	H107	H106
Operating income, as reported	\$2.8	\$3.6	\$4.6	\$4.9	\$3.5	\$10.6	\$12.6	\$22.2	\$12.8	\$8.6	\$24.4	\$17.2
Add: Equity compensation expense	0.4	0.3	0.8	0.6	1.1	1.0	2.2	1.9	0.4	0.2	0.7	0.4
Add: Receivable reserve	--	--	--	--	8.3	--	8.2	--	--	--	--	--
Adjusted Operating Income	\$3.2	\$3.9	\$5.4	\$5.5	\$12.8	\$11.6	\$23.0	\$24.1	\$13.2	\$8.8	\$25.1	\$17.6

Proforma Annual Compound Growth Rate ("CAGR") on a Net Revenue Basis

	YR 2003 to YR2006	
	Total	inVentiv Commercial**
CAGR%, as reported	46.1%	17.5%
Less: Acquisition CAGR%	27.9%	5.8%
CAGR%, proforma	18.2%	11.7%

** inVentiv Communications and inVentiv Clinical were not part of the company in 2003 and thus the GAAP reconciliations are not meaningful for those segments.

Proforma Growth Rate on a Net Revenue Basis

	H107 vs H106			
	Total	inVentiv Communications	inVentiv Commercial	inVentiv Clinical
Growth%, as reported	24.2%	38.9%	14.6%	25.2%
Less: Acquisition Growth%	9.6%	24.9%	3.8%	1.6%
Growth%, proforma	14.6%	14.0%	10.8%	23.6%

Adjusted Free Cash Flow

(in millions)	For the three months ended June 30, 2007	For the three months ended March 31, 2007	For the three months ended Dec. 31, 2006
Net income, reported	\$7.3	\$10.5	\$9.8
Add: Equity compensation expense	2.5	2.5	2.0
Add: Receivable reserve	8.2	--	--
Add (Subtract): Derivative interest	0.3	0.3	0.3
Net Income, adjusted	18.3	13.3	12.1
Add: Depreciation	4.6	3.9	3.9
Add: Amortization	2.1	1.8	1.4
Deduct: Property, Plant & Equipment	(1.9)	(2.3)	(1.3)
Deduct: Capital Leases	(3.6)	(3.8)	(4.3)
Free Cash Flow, adjusted	\$19.5	\$12.9	\$11.8



health